Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH002 as a Contrast Agent in Cardiac Echocardiography
NCT06815627Phase 3Active, not recruiting
- Sponsor
- Trust Bio-sonics Inc.
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of perflutren lipid microspheres in heart disease, sponsored by Trust Bio-sonics Inc. Primary endpoints: Left Ventricular Endocardial Border Delineation at 10 months and Left Ventricular Opacification at 10 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
heart disease
Beyond the preview
Go deeper on NCT06815627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815627.